Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

NCT ID: NCT01161979

Last Updated: 2010-07-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-01-31
• Study Completion Date: 2005-03-31

Brief Summary

The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Zonisamide 100 mg Capsule to that of Zonegran® 100 mg Capsule after a single, one-capsule dose in subjects fed a high standard fat meal.

Detailed Description

This was an open label, randomized, balanced, single dose, two-period, two-treatment, two-sequence crossover study, performed under fed conditions. Subjects were confined to the SFBC Clinical Research Facility from at least 10 hours prior to drug administration, until after the 24-hour post-dose blood draw, in each period. The treatment phases were separated by a washout period of 28 days.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Zonisamide

Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited

Group Type: EXPERIMENTAL

Zonisamide

Intervention Type: DRUG

Zonisamide capsules 100 mg

Zonegran

Zonegran Capsules 100 mg of EISAI INC

Group Type: ACTIVE_COMPARATOR

Zonegran

Intervention Type: DRUG

Zonegran Capsules 100 mg of EISAI INC

Interventions

Zonisamide

Zonisamide capsules 100 mg

Intervention Type: DRUG

Zonegran

Zonegran Capsules 100 mg of EISAI INC

Intervention Type: DRUG

Other Intervention Names

Zonegran Capsules 100 mg

Eligibility Criteria

Inclusion Criteria

• Is the individual a healthy, normal adult man or non-child bearing potential woman who volunteers to participate?
• Is s/he at least 18 years of age?
• Is his/her BMI between 19 and 30, inclusive?
• Is s/he considered reliable and capable of understanding his/her responsibility and role in the study?
• Has s/he provided written informed consent?

Exclusion Criteria

• Does the individual have a history of allergy or hypersensitivity to zonisamide or sulfonamides?
• Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
• Does s/he have serious psychological illness?
• Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse?
• Does s/he have a positive urine drug screen, or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test?
• Has s/he consumed grapefruit or grapefruit juice during the 7-day period preceding study initiation?
• Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken?
• Has s/he used any prescription drug during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
• Is s/he unable to refrain from the use of all concomitant medications during the study?
• Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?
• Has s/he donated plasma during the two week period preceding study initiation?
• Has s/he received an investigational drug during the 30 day Period preceding study initiation?

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Dr. Reddy's Laboratories Limited

Principal Investigators

Antonio R Pizarro, M.D

Role: PRINCIPAL_INVESTIGATOR

SFBC Ft. Myers, Inc

Locations

SFBC Ft. Myers, Inc.

Fort Myers, Florida, United States

Countries

United States

Other Identifiers

40578

Identifier Type: -

Identifier Source: org_study_id